The discovery of intracellular signaling networks that drive oncogenic processes when aberrantly activated has led to the development of molecularly targeted agents for the treatment of various cancers. 1, 2 Their targeted action spares normal cells, thus improving efficacy and health-related quality of life (HRQoL). Although systemic adverse events (AEs) characteristic of conventional cytotoxic agents (eg, myelosuppression, nausea, vomiting) 3 are typically not encountered, dermatologic AEs (affecting the skin, hair, nails, and mucosae) are common because some of the signaling pathways inhibited are also essential for cutaneous homeostasis. 4 Skin eruptions (rashes), xerosis, pruritus, photosensitivity, pigmentary changes, fissures, hand-foot skin reaction, and hair and/or nail changes are some of the most commonly encountered targeted therapyeinduced dermatologic AEs. 5 Although not life threatening, they can negatively affect patients' HRQoL and impair psychosocial functioning and activities of daily living. 6, 7 Furthermore, they often result in dose reductions, interruptions, or even discontinuation of therapy, which may lead to suboptimal management of the cancer itself and result in poorer outcomes. 8 Whereas the incidence and risk of some of the targeted therapyeinduced dermatologic AEs have been previously estimated, 9 ,10 that of dermatologic pigmentary AEs (dpAEs) is not known. The latter are of particular concern because of their persistence, resistance to therapy, and negative impact on psychosocial well-being and HRQoL. Therefore, we conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of targeted therapyeinduced dermatologic pigmentary AEs.
METHODS

Data source
We searched all targeted anticancer agents (n = 64) approved by the US Food and Drug Administration (www.FDA.gov) in January 2017 (Appendix I; available at http://www.jaad.org). A PubMed search was conducted using the generic name of targeted agents (eg, afatinib) as the key word. The search was limited to phase II and phase III randomized clinical trials (RCTs) and nonrandomized clinical trials published in English (from January 1998 through January 2017). We also reviewed abstracts and virtual meeting presentations (from January 2004 through January 2017) posted on the American Society of Clinical Oncology website to further identify relevant clinical trials. In addition, an independent search on the Web of Science database was conducted to ensure that no other studies were missed. We reviewed each publication and retrieved data only from complete and/or the most recent reports if duplicate publications were identified. Extracted information included patient characteristics, study design, treatment regimen, study results, and safety data.
Study selection
The US Food and Drug Administration approves targeted therapies at a specific dose in the treatment of cancer. Therefore, we excluded clinical trials using drugs at unapproved doses (eg, phase I studies) to determine the incidence and risk of dpAEs at the dosing level meaningful for clinicians. We also excluded trials that combined targeted agents with other chemotherapeutic agents and/or treatment modalities.
The dpAEs in the studies were reported as: hyperpigmentation, hypopigmentation, depigmentation, repigmentation, dyspigmentation, discoloration, color change, and vitiligo of either the skin, hair, or nails. Studies that met the following criteria were selected for final analysis: (1) prospective phase II or III clinical trial in patients with cancer; (2) assignment of participants to treatment with the targeted agent at the approved dose; and (3) availability of data regarding the incidence of pigmentary changes.
Clinical end points
The clinical end points were extracted from the safety profile in each trial. The dpAEs for skin were recorded according to the National Cancer Institute's Common Toxicity Criteria (version 2.0), or the Common Terminology Criteria for AEs (versions 3.0 and v4.0). The grading of dpAEs in the skin in version 2.0 is described as follows: grade 0, none; grade 1, localized; and grade 2, generalized. In version 3.0, the description was updated to hyperpigmentation and hypopigmentation, as There is an increased risk of development of targeted therapyeinduced pigmentary changes, but the causal agents and specific risks are not well described. Understanding targeted therapyeinduced pigmentary changes is critical for appropriate management to improve this psychosocially impactful adverse event.
follows: grade 1, slight or localized, and grade 2, marked or generalized. Version 4.0 further stratifies hyperpigmentation and hypopigmentation by body surface area (BSA) involvement as follows: grade 1, covering less than 10% of the BSA and having no psychosocial impact, and grade 2, covering more than 10% of the BSA and associated psychosocial impact. However, none of the studies in our meta-analysis utilized the Common Terminology Criteria for AEs, version 4.0. Lastly, given that pigmentary changes are not considered life threatening, there is no high-grade designation for these AEs.
Statistical analysis
All statistical analysis was performed by using Comprehensive Meta-Analysis program (version 2.0, Biostat, Englewood, NJ). The numbers of patients with pigmentary AEs in the treatment and control groups (as applicable) were identified from the selected clinical trials. The incidence and 95% confidence intervals (CIs) were calculated for each trial. For studies with a control arm, the relative risk (RR) of pigmentary AEs was also calculated.
For meta-analysis, both the fixed-effects (weighted with inverse variance) and the randomeffects models were given consideration for meta-analysis. The Cochran Q statistic was calculated for each meta-analysis to determine the heterogeneity of the included trials. For P values of the Cochran Q statistic less than 0.1, the assumption of homogeneity was deemed invalid, and the random-effects model was used after exploring the cause of heterogeneity. Barring this phenomenon, both the fixed-effects and random-effects models were reported. A 2-tailed P value less than .05 was established as statistically significant.
Systematic review of published case reports and case series
We also reviewed case reports and series to understand the clinical characteristics of dpAEs, as they are not reported in clinical trial publications. For this portion of the study, the following PubMed search strategy was used (last performed in January 2017): generic drug name AND (albinism OR bronz* OR dark* OR darkening OR depigmentation OR discoloration OR dyschromia OR excessive pigmentation OR hyperpigmentation OR hypopigmentation OR light* OR lightening OR melanosis OR poliosis OR repigmentation OR vitiligo OR whit*). The results were narrowed down to case reports and case series published in English. In addition, a manual search of the bibliography from retrieved reports was also performed. One of the authors (J.D.) reviewed all the identified manuscripts and extracted the following data onto an Excel spreadsheet: age, sex, race, underlying cancer, clinical findings, types of dyspigmentation including sites of involvement, pathology findings (if available), drug (including dosing), dose alterations, outcomes, number of cases, first author, and year of publication.
RESULTS
Search results
Our literature search yielded a total of 7604 potentially relevant studies, of which 36 clinical trials that involved targeted anticancer therapies met the inclusion criteria and were included in the final analysis (Fig 1) . The latter included phase II (n = 24) and phase III [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] (n = 12) trialsdall investigating solid organ malignancies. In all, 8052 patients (controls [n = 3648] and drug [n = 4404]) were analyzed across trials using cabozantinib, imatinib, ipilimumab, nivolumab, pazopanib, pembrolizumab, sorafenib, or sunitinib, which represented the 8 major drugs of the 64 (12.5%) included in the search. The data were analyzed separately for dpAEs of the skin and hair.
Incidence of all-grade pigmentary changes in skin
Data for all-grade dpAEs of skin were available for 6538 patients (across 28 clinical trials) treated with a targeted agent. The calculated overall incidence across all studies was 17.7% (95% CI, 11.9-25.4) according to the random-effects model (heterogeneity test: Q = 416.4, I 2 = 93.5, P \.001) (Fig 2, A) . The lowest incidence, 0.7%, was noted in the pazopanib arm (n = 554) of a randomized, open-label, phase III trial involving patients with metastatic renal cell carcinoma. 39 The highest incidence, 75%, was noted in a phase II study of sunitinib (n = 24) in patients with relapsed or refractory small cell lung cancer. 17 The drugwise summary incidences of all-grade pigmentary changes are provided in Table I . [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Incidence of all-grade pigmentary changes in hair
In all, we identified 14 clinical trials (involving 3319 evaluable patients) that reported hair color (Fig 2, B) . The lowest incidence, 3.7%, was noted in the sunitinib arm (n = 375) of a randomized, double-blinded, phase III trial involving patients with metastatic renal cell carcinoma 41 ; in an open-label extension study to evaluate the safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (n = 80), the incidence of hair color changes was highest at 43.8%. 43 Relative risk of all-grade pigmentary changes in skin
To estimate the relative risk (RR) of these changes in patients receiving targeted therapies as compared with placebo, a pooled meta-analysis was performed by using RCTs as the control arm. All-grade skin pigmentary changes were noted in 428 of 3301 patients receiving targeted therapies [35] [36] [37] [38] [39] [40] [41] as opposed to in none of 360 patients who received best supportive care alone. 41 The calculated overall RR for all-grade changes was 93.7 (95% CI, 5.86-1497.164; P \ .001), according to the random-effects model. The calculated high-grade RR was 2.371 (95% CI, 0.134-42.003; P = .556).
Relative risk of all-grade pigmentary changes in hair
A meta-analysis of RR for all-grade hair color changes associated with targeted agents versus controls was performed on 3 RCTs. 42, 44, 46 All-grade hair color changes were noted in the 187of 536 patients receiving targeted therapies, as compared with those in the 5 of 314 patients who received best supportive care alone. The calculated RR was 20.1 (95% CI, 8.35-48.248; P \ .001) according to the fixed-effects model. The calculated high-grade RR was 2.134 (95% CI, 0.224-20.355; P = .510).
Case reports and case series
Our search strategy yielded 53 publications (2002-2017) reporting on targeted anticancer therapyeinduced dpAEs involving the skin, hair, nails, and mucosae: 45 were case reports (n = 45 patients) and 8 were case series (n = 25 patients), with single-case reporting representing the majority (45 of 53 patients [85%]). Given the case-level nature of the reports, we conducted a pooled analysis and provided a summary of our findings (Table II S1-S53 )d the raw data pertaining to all cases, their description, and references are provided in Appendix II (available at http://www.jaad.org).
The J AM ACAD DERMATOL VOLUME 77, NUMBER 5 The skin appeared to be the most commonly affected site, followed by the mucosa, hair, and nails. Although generalized skin involvement did occur (n = 10), localized affliction of the face (n = 36), trunk (n = 10), hands and/or feet (n = 8) and legs (n = 8), and arms (n = 7) was also seen; no specific patterns were identifiable. The outcome of skin dpAEs was noted in 11 of 50 cases (22.0%); resolution in 7 of 50 (14.0%), and persistence in 4 of 50 cases (8.0%). The information pertaining to reversibility was not described in the rest. The breakpoint cluster regioneabelson inhibitor imatinib was responsible for the majority of skin-related dpAEs in this pooled analysis of cases. In cases in which hair was affected, scalp hair involvement predominated (10 of 13 cases [76.9%]), although virtually all hair-bearing areas appear susceptible; inhibitors of the breakpoint cluster regioneabelson and vascular endothelial growth factor receptor were the most common culprits. Nail dpAEs included hyperpigmentation and yellow discoloration in a total of 5 cases. Mucosal dpAEs were seen exclusively with imatinib (n = 17) and described as a blue-gray to brown discoloration.
DISCUSSION
In this study, we determined the incidence and risk of targeted anticancer therapyeinduced dpAEs from the safety data of published clinical trials and attempted to analyze the clinical characteristics by reviewing pertinent case reports/series. We found that the overall incidence of dpAEs in patients exposed to targeted anticancer therapies is high (17.7% in the case of skin, 21.5% in the case of hair). The targeted agents imatinib, cabozantinib, nivolumab, pazopanib, pembrolizumab, sorafenib, and sunitinib appeared to be the most common culprits.
The pathophysiology of targeted anticancer therapyeinduced dpAEs appears to be multifactorial and remains poorly understood. 47 Pigmentary changes associated with imatinib, a tyrosine kinase inhibitor, are well documented in the literature, with the most commonly described clinical phenotype being reversible, dose-related hypopigmentation. 48, 49 In vitro studies have demonstrated that imatinib may decrease skin pigmentation by inhibiting tyrosinase activity, likely through blockade of the c-Kit pathway and platelet-derived growth factor inhibition. 50 Interestingly, paradoxical cases of imatinib-associated hyperpigmentation have also been described, [51] [52] [53] although the mechanisms underlying these differential reactions remain unclear (Fig 3, A) .
Similarly, dpAEs associated with multikinase inhibitors are likely due to inhibition of c-kit, a known regulator of melanogenesis. C-kit is uniquely expressed in melanocytes and plays a critical role in melanocyte development, differentiation, and maintenance. 54 Mutations in c-kit are associated with hypopigmentation syndromes such as piebaldism and vitiligo. 55, 56 The nonselective multikinase inhibitors, cabozantinib, pazopanib, sorafenib, and sunitinib are probably associated with c-kit inhibition, although perhaps not through a direct effect on the KIT receptor, as with imatinib.
In the case of ipilimumab, however, the pigmentary changes appear to be a direct result of cytotoxic T-lymphocyte antigen-4 inhibition and consequent immune system activation, 57 including against the melanocytes.
58 Surprisingly, clinical depigmentation may serve as a surrogate marker for responsiveness to anticancer treatment, with the appearance of vitiligo-like melanoma-associated hypopigmentation portending a favorable response to therapy. 59 Finally, vitiligo-like lesions that occur during treatment with selective PD-1 inhibitors, such as pembrolizumab and nivolumab, have been reported in up to 25% of patients and may be associated with a clinical benefit (Fig 3, B) . 60 A recent study suggests a unique clinical phenotype and pathophysiological pathway that implicates a CD8 T-cell immune response distinct from spontaneously occurring vitiligo. 61 Current management strategies focus on pre-emptive approaches and patient education rather than on symptom management, because termination of drug exposure typically leads to resolution of the dpAEs. Patients should also be advised to use appropriate ultraviolet protection, as individuals who experience hypopigmentation may be at an increased risk for photosensitivity disorders.
Our meta-analysis has several limitations. First, dpAEs are asymptomatic and patients are less likely to notice and/or report them. Second, the assessment and reporting of dpAEs may be variable across health care providers and institutions, which could have affected safety reporting in clinical trials. Therefore, these inconsistencies may have resulted in the under-reporting, and consequently, underestimation of the incidence of targeted anticancer therapyeinduced dpAEs.
The study of AEs, especially dermatologic, has yet to keep up with the pace at which newer targeted anticancer drugs are being approved. Herein, we have shown that dpAEs are being encountered by a significant number of patients with cancer. This phenomenon is of particular importance because these events bear the potential to negatively affect patients' quality of life and psychosocial well-being, in addition to being long-lasting and challenging to treat. Moreover, the use of these drugs is widening, 
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AE, Adverse event; Bcr-abl, breakpoint cluster regioneabelson; BRAF, B-Raf proto-oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor; JAK, Janus kinase; mTOR, mammalian target of rapamycin; PD-1, programmed cell death 1; VEGFR, vascular endothelial growth factor receptor.
suggesting that these AEs could be increasingly encountered. Therefore, there is an urgent need to educate patients and health care providers and develop effective management strategies. Further investigation into the pathophysiology and management of dpAEs is warranted to ensure optimal therapy and improve patients' quality of life. By understanding the pathogenesis and clinical manifestations of these AEs, dermatologists play a critical role in guiding oncologic therapy by minimizing unwarranted dose reduction and dose stoppage.
APPENDIX I. LIST OF ALL TARGETED AGENTS SEARCHED FOR TO IDENTIFY STUDIES REPORTING DERMATOLOGIC PIGMENTARY ADVERSE EVENTS (N 5 64)
